Christian Johann Lerche

Christian Johann Lerche

Auto-generated profile, based on publicly available information

Christian Johann Lerche

Department of Clinical Microbiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 April 2017 in APMIS
Verified
Journal Article
Closed access
PDF file
CMClaus Moser
Claus Moser
Hannah TrøstrupHannah Trøstrup
Hannah Trøstrup
CLChristian Johann Lerche
Christian Johann Lerche
MKMete Kolpen
Mete Kolpen
LLLaura Line
Laura Line
PJPeter Østrup Jensen
Peter Østrup Jensen

14 April 2019 in APMIS
Verified
Journal Article
Closed access
PDF file
CMClaus Moser
Claus Moser
CLChristian Johann Lerche
Christian Johann Lerche
KTKim Thomsen
Kim Thomsen
THTom Hartvig
Tom Hartvig
JSJens Schierbeck
Jens Schierbeck
NHNiels Høiby
Niels Høiby

1 September 2017 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
CLC.J. Lerche
C.J. Lerche
LCL.J. Christophersen
L.J. Christophersen
MKMete Kolpen
Mete Kolpen
PNP.R. Nielsen
P.R. Nielsen
Hannah TrøstrupHannah Trøstrup
Hannah Trøstrup
CMClaus Moser
Claus Moser

1 November 2017 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
MKMete Kolpen
Mete Kolpen
CLChristian J. Lerche
Christian J. Lerche
KKKasper Nørskov Kragh
Kasper Nørskov Kragh
TSThomas Sams
Thomas Sams
KKKlaus Koren
Klaus Koren
PJPeter Østrup Jensen
Peter Østrup Jensen
Chronic Pseudomonas aeruginosa lung infection is characterized by the presence of endobronchial antibiotic-tolerant biofilm, which is subject to strong oxygen (O 2 ) depletion due to the activity of surrounding polymorphonuclear leukocytes. The exact mechanisms affecting the antibiotic susceptibility of biofilms remain unclear, but accumulating evidence suggests that the efficacy of several bactericidal antibiotics is enhanced by stimulation of aerobic respiration of pathogens, while lack of O 2 increases their tolerance. In fact, the bactericidal effect of several antibiotics depends on active aerobic metabolism activity and the endogenous formation of reactive O 2 radicals (ROS). In this study, we aimed to apply hyperbaric oxygen treatment (HBOT) to sensitize anoxic P. aeruginosa agarose biofilms established to mimic situations with intense O 2 consumption by the host response in the cystic fibrosis (CF) lung. Application of HBOT resulted in enhanced bactericidal activity of ciprofloxacin at clinically relevant durations and was accompanied by indications of restored aerobic respiration, involvement of endogenous lethal oxidative stress, and increased bacterial growth. The findings highlight that oxygenation by HBOT improves the bactericidal activity of ciprofloxacin on P. aeruginosa biofilm and suggest that bacterial biofilms are sensitized to antibiotics by supplying hyperbaric O 2 .

1 December 2019 in Biofilm
Verified
Journal Article
Open access
PJPeter Østrup Jensen
Peter Østrup Jensen
SMS.A. Møller
S.A. Møller
CLC.J. Lerche
C.J. Lerche
CMC. Moser
C. Moser
TBThomas Bjarnsholt
Thomas Bjarnsholt
MKMete Kolpen
Mete Kolpen
Bacteria and fungi show substantial increased recalcitrance when growing as infectious biofilms. Chronic infections caused by biofilm growing microorganisms is considered a major problem of modern medicine. New strategies are needed to improve antibiotic treatment of biofilms. We have improved antibiotic treatment of bacterial biofilms by reviving the dormant bacteria and thereby make them susceptible to antibiotics by means of reoxygenation. Here we review the rationale for associating lack of oxygen with low susceptibility in infectious biofilm, and how hyperbaric oxygen therapy may result in reoxygenation leading to enhanced bactericidal activity of antibiotics. We address issues of feasibility and potential adverse effects regarding patient safety and development of resistance. Finally, we propose means for supplying reoxygenation to antibiotic treatment of infectious biofilm with the potential to benefit large groups of patients.

26 November 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
SDSara Louise Dahl
Sara Louise Dahl
JWJoshua S. Woodworth
Joshua S. Woodworth
CLChristian Johann Lerche
Christian Johann Lerche
ECElisabeth Præstekjær Cramer
Elisabeth Præstekjær Cramer
PNPia Rude Nielsen
Pia Rude Nielsen
JCJack Cowland
Jack Cowland
Lipocalin-2 is a constituent of the neutrophil secondary granules and is expressed de novo by macrophages and epithelium in response to inflammation. Lipocalin-2 acts in a bacteriostatic fashion by binding iron-loaded siderophores required for bacterial growth. Mycobacterium tuberculosis (M.tb) produces siderophores that can be bound by lipocalin-2. The impact of lipocalin-2 in the innate immune response toward extracellular bacteria has been established whereas the effect on intracellular bacteria, such as M.tb, is less well-described. Here we show that lipocalin-2 surprisingly confers a growth advantage on M.tb in the early stages of infection (3 weeks post-challenge). Using mixed bone marrow chimeras, we demonstrate that lipocalin-2 derived from granulocytes, but not from epithelia and macrophages, leads to increased susceptibility to M.tb infection. In contrast, lipocalin-2 is not observed to promote mycobacterial growth at later stages of M.tb infection. We demonstrate co-localization of granulocytes and mycobacteria within the nascent granulomas at week 3 post-challenge, but not in the consolidated granulomas at week 5. We hypothesize that neutrophil-derived lipocalin-2 acts to supply a source of iron to M.tb in infected macrophages within the immature granuloma, thereby facilitating mycobacterial growth.